clinical trial · NCT03852433
Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)
Gilead Sciences·phase2·completed·n = 175
Chronic Hepatitis DeltaBulevirtidePeginterferon Alfa-2a (PEG-IFN alfa)
brief summary
The primary objective of this study is to evaluate the efficacy of bulevirtide in combination with pegylated interferon in participants with chronic hepatitis delta (CHD).
started
May 31, 2019
primary completion
Apr 5, 2022
completion
Sep 28, 2022
last updated
Oct 8, 2024
official title
A Multicenter, Open-label, Randomized Phase 2b Clinical Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Patients With Chronic Hepatitis Delta
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol